Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... addition of the "Global DNA Diagnostics Market ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... diagnostics Market (products, applications, techniques, end users and ...
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 WriteResult, ... services – has been working with a team of ... New Haven Farms Community Farming Collaborative to provide electronic ... solution. The study, which started in May, aims ... that provides participants weekly exposure to and participation in ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3
... ... of Bavituximab,s Mechanism of Action in ... - Results Further Support Future Clinical Trials Testing Bavituximab in ... Combination With Radiation Therapy -, TUSTIN, Calif., Sept. 4 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ...
... Sept. 4 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) ... Alexion Pharmaceuticals, will present at the,Bear Stearns 20th Annual ... on Tuesday, September 11, 2007. An audio webcast ... can,access the webcast at: http://www.alexionpharm.com . An archived ...
... To Maintain Roles as Vice Chairman of The Foundry and Advisor ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler ... and information technology investments, today announced the,addition of Hank Plain as ...
Cached Biology Technology:Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 2Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 3Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 4Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 5Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... a medical doctor. Yet he is seen as a hero ... D.H. was diagnosed with terminal lung cancer. , "In 2000 ... few months to live," said Pardini, a professor of biochemistry ... the University of Nevada, Reno. "But five years later, ...
... for treating Parkinson's diseases and other neurodegenerative disorders is getting ... brain is a complex organ with many different types of ... barrier erected by blood vessels and glial cells -- the ... of most drugs from the bloodstream. , But now scientists ...
... of history students have discovered the antler of an Irish Elk ... , Although the exact age of the antler has yet to ... (Megaloceros giganteus) lived around 11,000 years ago. The giant deer roamed ... the end of the last Ice Age, as the glaciers retreated ...
Cached Biology News:The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3Students discover 11,000 year old remains of Irish Elk 2
rat Leptin...
...
... with the xPONENT Software Interface is ... assays using Upstate's Beadlyte® reagents. This ... friendly xPONENT software developed by Luminex. ... for commercial or home-made multiplex kits. ...
... L samples, featuring 24-position turntable. Provides up to 30 minutes of walkaway time. Automatic ... and record keeping. RS-232 port. ... ... ...
Biology Products: